Drugs / Murine CART19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04276870 | Mar 2020 → Mar 2028 expected | B-lymphoblastic leukemia/lymphoma MLL rearranged, central nervous system non-hodgkin lymphoma | Stephan Grupp MD PhD | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Murine CART19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04276870 ↗ |
| Known as | CART19 | “CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ” NCT04276870 ↗ |
| Modality | Cell therapy | “CART19 cells transduced with a lentiviral vector” NCT04276870 ↗ |
| Route | Intravenous | “administered by IV injection” NCT04276870 ↗ |
| Target | CD19 | “express anti-CD19 scFv:41-BB:TCRζ” NCT04276870 ↗ |